BCL2L11 and chronic myelogenous leukemia, BCR-ABL1 positive: In summary, our results indicate that SB939 overcomes the BIM deletion polymorphism-induced TKI resistance and SB939 should be considered as a therapeutic strategy for CML patients with TKI resistance associated with this deletion polymorphism.